# Study to Evaluate the Safety and Immune Response of Two-Doses of Candidate Influenza Vaccine GSK 1557484A in Adults

> **NCT00510874** · PHASE1 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 780 (actual)

## Conditions studied

- Influenza

## Interventions

- **BIOLOGICAL:** Pumarix™
- **BIOLOGICAL:** Pandemrix ™

## Key facts

- **NCT ID:** NCT00510874
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-07-28
- **Primary completion:** 2008-06-17
- **Final completion:** 2008-10-24
- **Target enrollment:** 780 (ACTUAL)
- **Last updated:** 2018-08-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00510874

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00510874, "Study to Evaluate the Safety and Immune Response of Two-Doses of Candidate Influenza Vaccine GSK 1557484A in Adults". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT00510874. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*